Microbot Medical Advances Towards FDA Submission and Market Entry
Company Announcements

Microbot Medical Advances Towards FDA Submission and Market Entry

Microbot Medical ( (MBOT) ) has shared an update.

Microbot Medical Inc. has announced the successful completion of patient enrollment and follow-up in its ACCESS-PVI human clinical trial, paving the way for a 510(k) submission to the FDA by the end of 2024. The company is fast-tracking its go-to-market strategy, aiming to build a commercial infrastructure and hire a healthcare executive to lead sales efforts, pending FDA clearance expected in the second quarter of 2025. This advancement highlights Microbot’s commitment to revolutionizing endovascular procedures with its LIBERTY® Endovascular Robotic Surgical System.

For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMicrobot Medical Releases Investor Presentation Materials
TheFlyMicrobot announces it completed enrollment, follow p for ACCESS-PVI trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App